Q-omics provides the consensus-scored OR7G3 profile across patient tissues and cancer cell-line models. OR7G3 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, OR7G3 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, OR7G3 RNA expression shows 6,340 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SCLC, BRCA, and STAD as cancer lineages where OR7G3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7G3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7G3 survival associations across molecular data types. OR7G3 RNA expression shows survival associations in the most cancer types (8), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7G3 RNA expression–survival associations across cancer types. High OR7G3 expression shows unfavorable associations in SCLC, LUSC, SKCM, BLCA and LIHC, but favorable associations in ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify SCLC as the clearest survival context for OR7G3 RNA expression.
This table summarizes OR7G3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR7G3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7G3 shows lower tumor expression in BRCA. The BRCA box plot shows higher OR7G3 RNA expression in normal versus tumor tissue (log2 FC = −0.005, t-test p = .037).
This table shows molecular features associated with OR7G3 in patient tissues and cancer cell lines. In patient samples, OR7G3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, OR7G3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
